MedTrace Logo

APL-102 Capsule in Patients With Advanced Solid Tumors

NCT05055518 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-27

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

APL-102 Capsules

Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned. Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102.

Sponsors & Collaborators

  • Zhejiang CrownMab Biotech Co. Ltd

    collaborator INDUSTRY

  • Apollomics Inc.

    lead INDUSTRY

Principal Investigators

  • Yihebali Chi, PhD · Investigator

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-02
Primary Completion
2028-10-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05055518 on ClinicalTrials.gov